Navigation Links
NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
Date:3/18/2008

Also Announces Preliminary Agreement to Settle Litigation with US Labs

FT. MYERS, Fla., March 18 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM) today announced its results for the fourth quarter and full year of fiscal 2007. Significant accomplishments during the fourth quarter and calendar year included the following:

Fourth Quarter 2007 Highlights:

-- Revenue of $3.8 million, an increase of 115% year-over-year from Q4 06

-- Avg. Rev/Requisition increased 12.5% in Q4 07 from Q4 06

-- 22% sequential increase in revenues in Q4 07 vs. Q3 07

-- Hiring of additional 7 sales representatives

-- Roll-out of our NeoFLOW(TM) product

-- Almost tripling in size of our Ft. Myers, FL headquarters location

Fiscal Year 2007 Highlights:

-- Revenue of $11.5 million, an increase of 78% from $6.5 million in FY 06

-- Avg. Revenue/Test increased 8.6% in FY 07 from FY 06

-- Received CAP Accreditation for all specialties in all of our laboratory

locations

-- Continued rapid expansion of NeoFISH(TM) tech-only FISH services

Robert Gasparini, the Company's President, stated, "Before discussing our results, I am happy to report that we have reached a preliminary agreement to settle US Labs' claims against the Company and certain of its officers and employees. Under the terms of the agreement, NeoGenomics, on behalf of all defendants, will make a $250,000 payment to US Labs within thirty days and pay another $250,000 over the remaining nine months of this year. We expect that approximately 50% of these payments will be covered by our insurance policies. As a result, our fourth quarter financials include a $250,000 charge to cover the Company's expected portion of this settlement and an additional $125,000 charge to cover the Company's portion of the estimated legal fees incurred in Q1 up to the date of settlement. We are pleased to finally put this litigation beh
'/>"/>

SOURCE NeoGenomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Alpha Source, ... , will be exhibiting for the 13th consecutive ... Medical Instrumentation (AAMI) 2013 Conference and Expo. The ... distribute, and manufacture healthcare technologies. This year’s event ... Beach, California. , The three-day event draws ...
(Date:5/21/2013)... York , May 21, 2013 ... Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and ... IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and ... billion in 2011 and is expected to grow at ... reach an estimated value of USD 4.7 billion in ...
(Date:5/21/2013)... Md. , May 21, 2013  Synthetic Biologics, Inc. ... prevention and treatment of serious infectious diseases, announced today that ... the 2 nd Annual Marcum LLP MicroCap Conference on ... at the Grand Hyatt Hotel. Mr. Riley is ... A live webcast of Synthetic Biologics, presentation can be accessed ...
(Date:5/21/2013)... Ontario (PRWEB) May 21, 2013 ... scientists of the ITN to design the study, ... of two key clinical models used in the ... (EEC) and Nasal Allergen Challenge (NAC) models. Although ... by numerous publications, to date no direct comparison ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... HARTFORD, Conn., June 17 The Connecticut,Technology Council (CTC) ... in,partnership with accounting firm UHY LLP this November, to ... will be,recognized on the basis of revenue growth over ... and minimum revenues of $3 million in,the fourth year., ...
... Believe It Reflects,Unwillingness To Confront Issues and to Reveal His Inexperience and ... ... Analysts Available on BetterBiovail.com All Shareholders Urged to See New Video ... Shareholders,of Biovail Corporation (NYSE: BVF )(TSX: BVF) said today that a ...
... companies, The Integra Group of Brooklyn Park and, ... speed the path to ... cardiovascular medicine, BROOKLYN PARK, Minn. and SAN DIEGO, June ... Diego CA,NanoInterventions introduces the "Mouse Stent Model" for rapid screening ...
Cached Biology Technology:Connecticut Technology Council to Recognize Fast Growing Technology Companies 2Biovail Concerned Shareholders Want Open Debate 2Biovail Concerned Shareholders Want Open Debate 3NanoInterventions Launches New, Rapid Testing System for Coronary Stents 2NanoInterventions Launches New, Rapid Testing System for Coronary Stents 3
(Date:5/21/2013)... scientists have charted the path of insulin action in ... a comprehensive blueprint for understanding what goes wrong in ... Humphrey and Professor David James from Sydney,s Garvan Institute ... online edition of the prestigious journal Cell Metabolism ... plays a very important role in the body because ...
(Date:5/20/2013)... antibiotic colistin are also commonly resistant to antimicrobial ... a study in mBio , the online ... Cross-resistance to colistin and host antimicrobials LL-37 and ... attack, could mean that patients with life-threatening multi-drug ... immune response. Colistin is a last-line drug for ...
(Date:5/20/2013)... the lungs of the planet, inhales carbon dioxide as it ... grow parts that eventually fall to the ground to decompose ... , Until recently people believed much of the rain forest,s ... in the ocean. University of Washington research showed a decade ... though left open the question of how that was possible, ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
... that the primary bacteria behind tuberculosis can grow ... these bacterial communities, the research team recently reported ... a possible reason why human tuberculosis (TB) requires ... potential cause of the relapses that can nonetheless ...
... where fresh water is usually in very short supply but ... Journal of Global Environmental Issues , Peter van der Gaag ... hit on the idea of using the untapped energy from ... gypsum. Fresh water resources are scarce and will be ...
... On June 10, 2008 the scientific journal " Vaccine " ... Lab, Inc., demonstrating that a protein sequence important in neurodegenerative ... of vaccine adjuvants. The major component of every ... particular virus, bacteria or even cancer cells. Search for ...
Cached Biology News:Source of drug-tolerant tuberculosis possibly behind TB relapses, intensity of treatment 2Rocky water source 2A protein sequence associated with Huntington’s disease may become life-saving vaccine component 2
... serum is collected off the clot fasted non-Swiss Albino ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA N-11: ...
Recombinant Mouse Wnt-3a...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
... There are at least 20 structurally and ... the TGF-beta superfamily. BMPs were originally identified ... formation. They are also involved in embryogenesis ... BMPs regulate the growth, differentiation, chemotaxis and ...
Biology Products: